JP2014514536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014514536A5 JP2014514536A5 JP2013558218A JP2013558218A JP2014514536A5 JP 2014514536 A5 JP2014514536 A5 JP 2014514536A5 JP 2013558218 A JP2013558218 A JP 2013558218A JP 2013558218 A JP2013558218 A JP 2013558218A JP 2014514536 A5 JP2014514536 A5 JP 2014514536A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- soluble
- subject
- galectin
- biological sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161453782P | 2011-03-17 | 2011-03-17 | |
| US61/453,782 | 2011-03-17 | ||
| PCT/US2012/029500 WO2012141844A2 (en) | 2011-03-17 | 2012-03-16 | Methods predicting risk of an adverse clinical outcome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017181201A Division JP2018021926A (ja) | 2011-03-17 | 2017-09-21 | 有害臨床転帰のリスクを予測する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014514536A JP2014514536A (ja) | 2014-06-19 |
| JP2014514536A5 true JP2014514536A5 (enExample) | 2015-04-30 |
| JP6215713B2 JP6215713B2 (ja) | 2017-10-18 |
Family
ID=47009907
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013558218A Expired - Fee Related JP6215713B2 (ja) | 2011-03-17 | 2012-03-16 | 有害臨床転帰のリスクを予測する方法 |
| JP2017181201A Pending JP2018021926A (ja) | 2011-03-17 | 2017-09-21 | 有害臨床転帰のリスクを予測する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017181201A Pending JP2018021926A (ja) | 2011-03-17 | 2017-09-21 | 有害臨床転帰のリスクを予測する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US8728742B2 (enExample) |
| EP (2) | EP2686689B1 (enExample) |
| JP (2) | JP6215713B2 (enExample) |
| CN (2) | CN106940375B (enExample) |
| ES (2) | ES2750126T3 (enExample) |
| WO (1) | WO2012141844A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7432060B2 (en) | 2000-11-09 | 2008-10-07 | The Brigham And Women's Hospital, Inc. | Methods for diagnosis of cardiovascular disease |
| SI2336359T1 (sl) | 2002-05-09 | 2016-08-31 | The Brigham And Women's Hospital, Inc. | 1L1RL-1 kot marker kardiovaskularne bolezni |
| ES2529618T3 (es) | 2006-04-24 | 2015-02-23 | Critical Care Diagnostics, Inc. | Predicción de la mortalidad y detección de enfermedades graves |
| US20090305265A1 (en) * | 2006-04-27 | 2009-12-10 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
| PL2021796T3 (pl) | 2006-05-01 | 2012-07-31 | Critical Care Diagnostics Inc | Diagnozowanie choroby sercowo-naczyniowej |
| ES2542343T3 (es) * | 2006-05-02 | 2015-08-04 | Critical Care Diagnostics, Inc. | Diagnóstico diferencial entre enfermedad pulmonar y cardiovascular |
| EP3093663B1 (en) | 2008-04-18 | 2018-06-13 | Critical Care Diagnostics, Inc. | Predicting risk of major adverse cardiac events |
| EP2556090B1 (en) | 2010-04-09 | 2016-02-24 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
| EP2686689B1 (en) | 2011-03-17 | 2019-08-07 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| CA2842072A1 (en) | 2011-07-18 | 2013-01-24 | James V. Snider | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
| WO2013173778A1 (en) | 2012-05-18 | 2013-11-21 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
| WO2014028875A1 (en) | 2012-08-16 | 2014-02-20 | Critical Care Diagnostics, Inc. | Methods for predicting risk of developing hypertension |
| MX375520B (es) | 2012-08-21 | 2025-03-06 | Critical Care Diagnostics Inc | Estratificación de riesgo para marcador múltiple. |
| CN104521298B (zh) * | 2013-08-08 | 2018-07-03 | 华为技术有限公司 | 传输信号的方法、网络侧设备和用户设备 |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| EP3448245A1 (en) * | 2016-04-25 | 2019-03-06 | Siemens Healthcare Diagnostics Inc. | Diagnostic method(s) for detecting and treating post-infarct myocardium remodeling and diffuse myocardial fibrosis |
| CA3070446A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | Treating cancer by blocking the interaction of tim-3 and its ligand |
| US10799138B2 (en) | 2018-04-05 | 2020-10-13 | University Of Maryland, Baltimore | Method of administering sotalol IV/switch |
| RU2677611C1 (ru) * | 2018-04-16 | 2019-01-17 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Способ прогнозирования неблагоприятных сердечно-сосудистых событий в течение 12 месяцев у больных хронической сердечной недостаточностью с рецидивом стенокардии после реваскуляризации миокарда |
| US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
| US12396970B2 (en) | 2021-08-20 | 2025-08-26 | AltaThera Pharmaceuticals LLC | Anti-arrhythmic compositions and methods |
| US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN113425271B (zh) * | 2021-05-20 | 2024-02-06 | 上海小芃科技有限公司 | 日间手术出院判断方法、装置、设备及存储介质 |
| WO2024092136A2 (en) * | 2022-10-28 | 2024-05-02 | Memorial Sloan-Kettering Cancer Center | Machine learning modeling for inpatient prediction |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6176962B1 (en) | 1990-02-28 | 2001-01-23 | Aclara Biosciences, Inc. | Methods for fabricating enclosed microchannel structures |
| GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
| US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
| ES2374621T3 (es) | 1997-04-02 | 2012-02-20 | The Brigham And Women's Hospital, Inc. | Medios para evaluar el perfil de riesgo de un individuo de sufrir una enfermedad ateroesclerótica. |
| US6210976B1 (en) | 1997-06-10 | 2001-04-03 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
| US5842787A (en) | 1997-10-09 | 1998-12-01 | Caliper Technologies Corporation | Microfluidic systems incorporating varied channel dimensions |
| GB9827348D0 (en) | 1998-12-12 | 1999-02-03 | Univ Leicester | Natriuretic peptide |
| WO2000035473A2 (en) | 1998-12-18 | 2000-06-22 | Scios Inc. | Methods for detection and use of differentially expressed genes in disease states |
| WO2000062076A1 (en) | 1999-04-13 | 2000-10-19 | Hsu Daniel K | Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma |
| AU5309600A (en) | 1999-06-02 | 2000-12-18 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| WO2001070817A1 (en) | 2000-03-21 | 2001-09-27 | Medical & Biological Laboratories Co., Ltd. | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
| CA2388061A1 (en) | 2000-08-22 | 2002-02-28 | The Brigham And Women's Hospital, Inc | Diagnosis and treatment of cardiovascular conditions |
| US7432060B2 (en) | 2000-11-09 | 2008-10-07 | The Brigham And Women's Hospital, Inc. | Methods for diagnosis of cardiovascular disease |
| US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| US20030004132A1 (en) * | 2001-06-22 | 2003-01-02 | Yan Chang | Method and material for treating immune diseases |
| WO2003022987A2 (en) | 2001-07-26 | 2003-03-20 | Eos Biotechnology, Inc. | Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection |
| US6810284B1 (en) | 2001-11-21 | 2004-10-26 | Pacesetter, Inc. | Implantable cardiac stimulation system and method for monitoring diastolic function |
| SI2336359T1 (sl) | 2002-05-09 | 2016-08-31 | The Brigham And Women's Hospital, Inc. | 1L1RL-1 kot marker kardiovaskularne bolezni |
| AU2003299441A1 (en) | 2002-12-19 | 2004-07-14 | Centre National De La Recherche Scientifique - Cnrs | Nf-hev compositions and methods of use |
| US20040133079A1 (en) | 2003-01-02 | 2004-07-08 | Mazar Scott Thomas | System and method for predicting patient health within a patient management system |
| WO2004111654A2 (en) | 2003-06-06 | 2004-12-23 | Ciphergen Biosystems, Inc. | Serum biomarkers in ischaemic heart disease |
| EP1522857A1 (en) | 2003-10-09 | 2005-04-13 | Universiteit Maastricht | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| US20050123451A1 (en) | 2003-10-31 | 2005-06-09 | Hiroshi Nomura | System and apparatus for body fluid analysis using surface-textured optical materials |
| EP2386657B1 (en) | 2003-11-26 | 2014-01-08 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
| US20050196817A1 (en) | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| JP2005291899A (ja) | 2004-03-31 | 2005-10-20 | Akira Matsumori | 心疾患の検査法 |
| EP1731910A1 (en) | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
| ES2529618T3 (es) | 2006-04-24 | 2015-02-23 | Critical Care Diagnostics, Inc. | Predicción de la mortalidad y detección de enfermedades graves |
| US20090305265A1 (en) * | 2006-04-27 | 2009-12-10 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
| PL2021796T3 (pl) | 2006-05-01 | 2012-07-31 | Critical Care Diagnostics Inc | Diagnozowanie choroby sercowo-naczyniowej |
| ES2542343T3 (es) | 2006-05-02 | 2015-08-04 | Critical Care Diagnostics, Inc. | Diagnóstico diferencial entre enfermedad pulmonar y cardiovascular |
| US8147817B2 (en) | 2006-05-04 | 2012-04-03 | The Brigham And Women's Hospital, Inc. | IL-33 in the treatment and diagnosis of diseases and disorders |
| EP2282757B1 (en) * | 2008-04-07 | 2013-05-22 | Kalobios Pharmaceuticals, Inc. | Neutralization of gm-csf for the treatment of heart failure |
| EP3093663B1 (en) | 2008-04-18 | 2018-06-13 | Critical Care Diagnostics, Inc. | Predicting risk of major adverse cardiac events |
| JP2011528115A (ja) * | 2008-07-14 | 2011-11-10 | エフ．ホフマン−ラ ロシュ アーゲー | 心不全を有する患者の診断、モニター及び治療の選択のためのマルチマーカーパネル |
| CA2742265C (en) * | 2008-10-29 | 2014-07-15 | Bg Medicine, Inc. | Galectin-3 immunoassay |
| EP2556090B1 (en) | 2010-04-09 | 2016-02-24 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
| EP2686689B1 (en) | 2011-03-17 | 2019-08-07 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| CA2842072A1 (en) | 2011-07-18 | 2013-01-24 | James V. Snider | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
| WO2013173778A1 (en) | 2012-05-18 | 2013-11-21 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
| WO2014028875A1 (en) | 2012-08-16 | 2014-02-20 | Critical Care Diagnostics, Inc. | Methods for predicting risk of developing hypertension |
| MX375520B (es) | 2012-08-21 | 2025-03-06 | Critical Care Diagnostics Inc | Estratificación de riesgo para marcador múltiple. |
| MX2016009060A (es) | 2014-01-10 | 2016-09-09 | Critical Care Diagnostics Inc | Metodos y sistemas para determinar el riesgo de falla cardiaca. |
| USD770057S1 (en) | 2014-04-14 | 2016-10-25 | Critical Care Diagnostics, Inc. | Blood test kit |
| USD800332S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| USD800333S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
| US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
| US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
-
2012
- 2012-03-16 EP EP12771826.0A patent/EP2686689B1/en active Active
- 2012-03-16 US US13/422,574 patent/US8728742B2/en active Active
- 2012-03-16 JP JP2013558218A patent/JP6215713B2/ja not_active Expired - Fee Related
- 2012-03-16 CN CN201610825849.1A patent/CN106940375B/zh not_active Expired - Fee Related
- 2012-03-16 WO PCT/US2012/029500 patent/WO2012141844A2/en not_active Ceased
- 2012-03-16 EP EP19190278.2A patent/EP3605104B1/en not_active Not-in-force
- 2012-03-16 CN CN201280023965.1A patent/CN103718046B/zh not_active Expired - Fee Related
- 2012-03-16 ES ES12771826T patent/ES2750126T3/es active Active
- 2012-03-16 ES ES19190278T patent/ES2897419T3/es active Active
-
2014
- 2014-05-01 US US14/267,487 patent/US9239333B2/en active Active
-
2016
- 2016-01-12 US US14/993,196 patent/US9823257B2/en not_active Expired - Fee Related
-
2017
- 2017-09-21 JP JP2017181201A patent/JP2018021926A/ja active Pending
- 2017-11-01 US US15/800,512 patent/US10393756B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014514536A5 (enExample) | ||
| De Boer et al. | State of the art: newer biomarkers in heart failure | |
| Whitaker et al. | Urinary mitochondrial DNA is a biomarker of mitochondrial disruption and renal dysfunction in acute kidney injury | |
| Boisot et al. | Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure | |
| Hricik et al. | Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury | |
| Meijers et al. | The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure | |
| Cracowski et al. | The potential of biomarkers in pulmonary arterial hypertension | |
| JP2011520098A5 (enExample) | ||
| CN101646945B (zh) | 利用CT-proET-1与NT-proBNP的组合进行急性冠状动脉综合征的诊断和风险分层 | |
| RU2018139780A (ru) | Способы и наборы диагностики и стратификации риска пациентов с ишемией | |
| RU2015108959A (ru) | Способы прогнозирования риска развития гипертензии | |
| JP2012507026A5 (enExample) | ||
| Solus et al. | Amino‐terminal fragment of the prohormone brain‐type natriuretic peptide in rheumatoid arthritis | |
| Pankow et al. | HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study | |
| WO2012058313A2 (en) | Novel biomarkers for cardiovascular injury | |
| JP2012507030A5 (enExample) | ||
| Caselli et al. | IL‐33/ST2 pathway and classical cytokines in end‐stage heart failure patients submitted to left ventricular assist device support: a paradoxic role for inflammatory mediators? | |
| JP2013539861A5 (enExample) | ||
| EP2376919A1 (en) | Combined natriuretic peptide assays | |
| Alharbi et al. | Predictors of a variceal source among patients presenting with upper gastrointestinal bleeding | |
| Perry et al. | Clinical-transcriptional prioritization of the circulating proteome in human heart failure | |
| CN115747329A (zh) | 用于预测肿瘤进展及预后的基因标志物组合、试剂盒及系统 | |
| Siasos et al. | Novel biomarkers in heart failure: usefulness in clinical practice | |
| Bruno et al. | Levels of N‐terminal pro brain natriuretic peptide are enhanced in people with the uncomplicated metabolic syndrome: a case‐cohort analysis of the population‐based Casale Monferrato study | |
| EP4025915B1 (en) | Assay for assessing heart failure |